ClinicalTrials.gg
RecruitingNCT07503275COLIBRIUpdated Nov 13, 2026

Functional Magnetic Resonance Imaging Study of Inhibitory Control in Bipolar Disorder and Major Depressive Disorder

An interventional study of Analysis of inhibitory control in Bipolar Disorder and Major Depressive Disorder, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by CHU de Reims · Not applicable, Interventional, and Basic science

How we know

Updated Nov 13, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.

Planned enrollment
46th of 79
120 · median 170
Started
2026
with 6 others
No phase
56 of 104
22 open now
Primary completion
2029-11
later than 33 of 37 live
Registered
100th of 104
by date
Lead sponsor
6 of 104
CHU de Reims

Among the 104 studies in Bipolar Disorder with a site in France, this one is the 46th largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2026, is one of 56 with no phase, reaches primary completion later than 33 of the 37 other live ones, and was the 100th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Bipolar Disorder with a site in France, or all of them as a file.
02

Study summary

Bipolar disorder and unipolar depressive disorder are two chronic mood disorders associated with a significant social impact, even during euthymic phases. Their differential diagnosis remains complex, particularly when bipolar disorder begins with a depressive episode. Identifying distinctive markers between these pathologies therefore represents a major clinical and economic challenge, as appropriate mood-stabilizing treatment can reduce healthcare costs and improve patients' functional outcomes.

Among potential biomarkers, executive functions-and more specifically inhibition-have received particular attention. Inhibitory deficits are observed in both disorders, including during euthymic states, and also among first-degree relatives, suggesting their potential as cognitive and cerebral endophenotypes. These deficits may help explain the difficulties in emotion regulation and impulsivity frequently observed in mood disorders.

Two components of inhibition are distinguished:

  1. Behavioral inhibition, which refers to the ability to stop an ongoing response.
  2. Interference control, which refers to the ability to resist distraction. These processes rely on partially distinct neural networks and operate at different stages of information processing. The few studies comparing these two components in bipolar disorder have shown contradictory results, and neuroimaging investigations have only partially explored these mechanisms, particularly their emotional dimension. It is, however, well established that patients with bipolar or depressive disorders show greater difficulties in executive tasks involving emotional stimuli than in purely cognitive tasks.

The study is expected to reveal:

  • Differences in brain activation between euthymic bipolar and unipolar depressive patients in regions involved in inhibitory control, modulated by the emotional content of the task.
  • Distinct cognitive performance profiles according to pathology, reflecting specific alterations in inhibitory and interference processes.

These findings should provide a better understanding of the differential neurocognitive bases of mood disorders. Identifying specific cognitive and neural profiles could contribute to more accurate differential diagnosis and to the personalization of therapeutic interventions, particularly through cognitive remediation strategies targeting executive and emotional deficits.

Read the detailed description

Bipolar disorder (BD) and unipolar depressive disorder (UDD) are chronic mood disorders that cause significant functional and social impairment, even during euthymic phases. The differential diagnosis between these two conditions remains challenging, especially when bipolar disorder initially manifests with a depressive episode, the most frequent onset pattern. Identifying reliable biomarkers that distinguish BD from UDD is therefore a major clinical and scientific objective. Early and appropriate introduction of mood-stabilizing treatments is associated with improved long-term outcomes and reduced healthcare costs through fewer hospitalizations.

Scientific Background and Rationale:

Executive dysfunctions, particularly inhibitory control deficits, have been consistently observed in both BD and UDD, including during remission. Similar deficits in first-degree relatives suggest that these alterations could represent cognitive or neural endophenotypes. Inhibition, defined as the ability to suppress a dominant or prepotent response, plays a central role in emotion regulation.

Inhibitory control can be divided into two complementary components:

  1. Behavioral inhibition, the ability to suppress or stop a prepotent motor response.
  2. Interference control, the ability to resist irrelevant or distracting information that interferes with ongoing cognitive processing.

Neuroimaging studies in healthy populations have revealed distinct but overlapping neural networks underlying these two processes. However, data on BD and UDD remain limited and sometimes inconsistent, particularly regarding the differential involvement of these two components and their modulation by emotional context.

Objectives:

The primary objective of this study is to investigate, using functional magnetic resonance imaging (fMRI), the brain circuits underlying the two mechanisms of inhibitory control - behavioral inhibition and interference control - in both their cognitive and emotional components, among euthymic patients with BD or UDD, compared with matched healthy controls.

Secondary objectives include:

  • Comparing cognitive performance between groups.
  • Exploring associations between cognitive performance, clinical characteristics (e.g., age at onset, number of episodes, symptom severity), and brain activation profiles.

Study Design:

This is a monocentric, prospective, cross-sectional study including four participant groups: patients with BD, patients with UDD, and their respective matched control groups. Each participant will complete three study visits:

  • Visit 1 (V1): Clinical assessment and inclusion. Participants will provide informed consent and undergo a standardized diagnostic evaluation (DSM-5 criteria), assessment of current mood symptoms, and collection of sociodemographic and clinical data.
  • Visit 2 (V2): Neuropsychological testing. A standardized battery will assess executive functions, including inhibition, interference control, cognitive flexibility, working memory, and processing speed.
  • Visit 3 (V3): MRI acquisition. Participants will undergo both structural (T1-weighted) and functional (BOLD) MRI scans while performing two experimental tasks targeting inhibitory control.

Experimental Paradigms and Imaging Procedures:

Two validated cognitive paradigms will be used:

  • Behavioral inhibition task (Stop-Signal task): assesses the ability to inhibit prepotent motor responses. Emotional and neutral stimuli will be randomly presented to explore emotional modulation of inhibitory processes.
  • Interference control task (Flanker task): assesses the ability to resist interference from cognitive or emotional distractors, isolating attentional control mechanisms.

MRI data will be acquired using a 3-Tesla scanner. Functional sequences will use gradient-echo echo-planar imaging optimized for BOLD contrast, with a temporal resolution of approximately 2 seconds and a spatial resolution of \~3 mm isotropic. High-resolution T1-weighted anatomical images (1 mm isotropic) will be acquired for normalization and morphometric analysis.

Data Analysis:

Preprocessing and statistical analyses will be performed using standard neuroimaging software. Data will undergo motion correction, spatial normalization to MNI space, and Gaussian smoothing.

First-level analyses will be conducted using a general linear model to model activation for cognitive and emotional conditions.

Second-level (group) analyses will use hierarchical mixed-effects models to identify between-group differences in neural activation patterns (BD vs. UDD vs. controls). Correlation analyses will explore relationships between brain activation, cognitive performance, and clinical variables.

Statistical significance will be set at p \< 0.05 family-wise error corrected for multiple comparisons, and p \< 0.001 uncorrected for exploratory analyses.

Innovation and Expected Outcomes:

This study is among the first to jointly investigate behavioral and interference components of inhibitory control in both cognitive and emotional domains in euthymic BD and UDD patients. The combination of neuropsychological and fMRI approaches will:

  • Characterize specific activation patterns underlying inhibitory control deficits.
  • Identify potential cognitive and neural endophenotypes distinguishing BD from UDD.
  • Clarify the influence of emotional context on inhibitory processing.
  • Explore correlations between clinical, cognitive, and neurofunctional data. These findings are expected to improve understanding of the differential pathophysiology of mood disorders, contribute to the development of objective diagnostic biomarkers, and guide targeted therapeutic interventions (e.g., cognitive remediation, emotion regulation strategies).
03

Conditions studied

  • Bipolar Disorder
  • Major Depressive Disorder

Keywords

  • fMRI
  • bipolar disorder
  • major depressive disorder
  • inhibitory control
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Group 1 and 2: Bipolar patients, Depressive patients

Inclusion criteria:

  • Patients between 18 and 65 years old, men or women, right-handed
  • Having a diagnosis of bipolar disorder or depressive disorder
  • No substantial change in treatment for 2 weeks preceding study enrollment
  • Being a native French speaker
  • Patients enrolled in the national healthcare insurance program
  • Consenting to participate to the study

Exclusion criteria:

  • The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence
  • A significant general medical illness, including neurological disorders or head trauma
  • to the use of MRI
  • A sensorial impairment uncorrected (visual and/or hearing)

Group 3 and 4: Healthy control participants

Inclusion criteria:

  • Participants between 18 and 65 years old, men or women, right-handed
  • Being a native French speaker
  • Patients enrolled in the national healthcare insurance program
  • Consenting to participate to the study

Exclusion criteria:

  • A diagnosis of schizophrenia or of bipolar disorder or of major depressive disorder according to criteria
  • The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence
  • Participants having one first-degree relative presenting an bipolar disorder or depressive disorder or schizophrenia according to DSM-5 criteria
  • A significant general medical illness, including neurological disorders or head trauma
  • Contraindication to the use of MRI
  • A sensorial impairment uncorrected (visual and/or hearing)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group 1: Bipolar patients

    Patients with a diagnosis of bipolar disorder

    Behavioral: Analysis of inhibitory control

  • Experimental
    Group 2: Major depressive patients

    Patients with a diagnosis of major depressive disorder

    Behavioral: Analysis of inhibitory control

  • Active comparator
    Group 3: Bipolar controls

    Healthy control participants matched to group 1

    Behavioral: Analysis of inhibitory control

  • Active comparator
    Group 4: Depressive controls

    Healthy control participants matched to group 2

    Behavioral: Analysis of inhibitory control

Interventions

  • BehavioralAnalysis of inhibitory control

    Investigation of neurofunctional characterization of inhibitory control using a comprehensive clinical, cognitive assessment and task-based MRI exams

06

What researchers measure

Primary outcomes

  1. fMRI activations during an behavioral inhibition task (emotional stop signal task)

    Participants will perform a gender discrimination task on emotional and non-emotional faces. Under Go conditions, the participant must respond. Under non-Go conditions, the frame of the image changes color and the participant must not respond. The faces express neutrality (50%) or anger (50%).

    Time frame: Day 0

  2. fMRI activations during an emotional interference control (emotional Flanker task)

    Participants were instructed to discriminate the gender of a target stimulus during an emotional Flanker task. The stimuli consist of faces expressing a neutral or angry emotion. The central face (the target) may display the same emotion (congruent condition) or a different emotion (incongruent condition) from the faces on the right and left (two flankers). Participants must say, as quickly and accurately as possible, what the gender of the central face is

    Time frame: Day 0

Secondary outcomes

  1. Psychological profiles: depression

    Evaluated through the Hamilton Depression Rating Scale (HAM-D). HAM-D is a widely used self-report scale to assess depressive symptoms consisting of 21 items, which has been validated in French. The total score is obtained by adding the scores of the 17 first items, the score ranging from 0 to 52, with higher scores indicating greater depression symptoms.

    Time frame: Day 0

  2. Psychological profiles: mania

    Evaluated through the Young Mania Rating Scale (YMRS). The YMRS is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items, the score ranging from 0 to 60 and higher scores indicating greater manic symptoms.

    Time frame: Day 0

  3. Psychological profiles: anxiety symptoms

    Anxiety severity is assessed with the Spielberger State-Trait Inventory (STAI) which is a 40-item scale, using a 4-point Likert scale for each item. This scale was used to measure both trait anxiety (how dispositionally anxious a person is across time and situations) and state anxiety (how anxious a person is feeling at a particular moment). The total score is obtained by adding items, the score ranging from 20 to 80. Higher scores indicate greater anxiety symptoms.

    Time frame: Day 0

  4. Social functioning: quality of life

    Evaluated through the World Health Organization Quality of Life (WHOQOL-BREF) quality of life assessment. The WHOQOL-BREF consists of 26 items scored in four domains: physical, psychological, social relationships, and environment. The score ranges from 0 to 100 with the higher score indicating a better quality of life.

    Time frame: Day 0

  5. Executive functions: verbal inhibition performance

    Evaluated through the Hayling Sentence Completion Test. The HCST consists of two sets of 15 sentences each having the last word missing. In the first section the examiner reads each sentence aloud and the participant has to simply complete the sentences, yielding a simple measure of response initiation speed. The second part of the Hayling requires participants to complete a sentence with a nonsense ending word (and suppress a sensible one), giving measures of response suppression ability and thinking time. The number of correct answers and the total time are recorded for each part. The higher the number of correct answers, the better the performance. The longer the response time, the lower the performance. For each part, the score ranges from 0 to 15.

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Nov 2029, 36 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 36 months is close to that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jun 2026 → Nov 2026, primary completion Sep 2029 → Nov 2029 and completion Dec 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 31, 2026
StartActual
Nov 3, 2026was Jun 2026
Primary completionEst.
Nov 2029was Sep 2029
CompletionEst.
Jan 2030was Dec 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Chu Reims · Reims, France
Show 1 removed
  • Chu Reims · Reims, France
Nov 13, 2026
Start date
Jun 2026→Nov 3, 2026 (actual)
Nov 13, 2026
Primary completion
Sep 2029→Nov 2029
Nov 13, 2026
Study completion
Dec 2029→Jan 2030
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Chu Reims · Reims, France
    Show 1 removed
    • Chu Reims · Reims, France
    Start date Jun 2026→Nov 3, 2026 (now actual)
    Primary completion Sep 2029→Nov 2029
    Study completion Dec 2029→Jan 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07503275
Lead sponsor
CHU de Reims
Collaborators
Public Mental Health Institution of the Marne
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Nov 3, 2026
Primary completion
Nov 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Martina TRAYKOVA
Contact
traykovam@epsm-marne.fr
0326402254 ext. 0033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion